- Diet
- Cancer
- Colorectal Cancer
- Prostate Cancer
- Breast Cancer
- Adenoid Cystic Carcinoma
- Amyloidosis
- Anal Cancer
- Appendix Cancer
- Astrocytoma - Childhood
- Ataxia-Telangiectasia
- Beckwith-Wiedemann Syndrome
- Bile Duct Cancer (Cholangiocarcinoma)
- Birt-Hogg-Dubé Syndrome
- Bladder Cancer
- Bone Cancer (Sarcoma of Bone)
- Brain Stem Glioma - Childhood
- Brain Tumor
- Breast Cancer - Inflammatory
- Breast Cancer - Metastatic
- Breast Cancer - Male
- Carney Complex
- Central Nervous System Tumors (Brain and Spinal Cord) - Childhood
- Cervical Cancer
- Childhood Cancer
- Cowden Syndrome
- Craniopharyngioma - Childhood
- Desmoid Tumor
- Desmoplastic Infantile Ganglioglioma, Childhood Tumor
- Ependymoma - Childhood
- Esophageal Cancer
- Ewing Sarcoma - Childhood and Adolescence
- Eye Melanoma
- Eyelid Cancer
- Familial Adenomatous Polyposis
- Familial GIST
- Familial Malignant Melanoma
- Familial Pancreatic Cancer
- Gallbladder Cancer
- Gastrointestinal Stromal Tumor - GIST
- Germ Cell Tumor - Childhood
- Gestational Trophoblastic Disease
- Head and Neck Cancer
- Hereditary Breast and Ovarian Cancer
- Hereditary Diffuse Gastric Cancer
- Hereditary Leiomyomatosis and Renal Cell Cancer
- Hereditary Mixed Polyposis Syndrome
- Hereditary Pancreatitis
- Hereditary Papillary Renal Carcinoma
- HIV/AIDS-Related Cancer
- Juvenile Polyposis Syndrome
- Kidney Cancer
- Laryngeal and Hypopharyngeal Cancer
- Leukemia - Acute Lymphoblastic - ALL - Childhood
- Leukemia - Acute Lymphocytic - ALL
- Leukemia - Acute Myeloid - AML
- Leukemia - Acute Myeloid - AML - Childhood
- Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia
- Leukemia - Chronic Lymphocytic - CLL
- Leukemia - Chronic Myeloid - CML
- Leukemia - Chronic T-Cell Lymphocytic
- Leukemia - Eosinophilic
- Li-Fraumeni Syndrome
- Liver Cancer
- Lung Cancer - Non-Small Cell
- Lung Cancer - Small Cell
- Lymphoma - Hodgkin
- Lymphoma - Hodgkin - Childhood
- Lynch Syndrome
- Lymphoma - Non-Hodgkin - Childhood
- Lymphoma - Non-Hodgkin
- Mastocytosis
- Medulloblastoma - Childhood
- Melanoma
- Meningioma
- Mesothelioma
- Multiple Endocrine Neoplasia Type 1
- Multiple Endocrine Neoplasia Type 2
- Multiple Myeloma
- MUTYH (or MYH)-Associated Polyposis
- Myelodysplastic Syndromes - MDS
- Nasal Cavity and Paranasal Sinus Cancer
- Nasopharyngeal Cancer
- Neuroblastoma - Childhood
- Neuroendocrine Tumor of the Gastrointestinal Tract
- Neuroendocrine Tumor of the Lung
- Neuroendocrine Tumor of the Pancreas
- Neuroendocrine Tumors
- Neurofibromatosis Type 1
- Neurofibromatosis Type 2
- Nevoid Basal Cell Carcinoma Syndrome
- Oral and Oropharyngeal Cancer
- Osteosarcoma - Childhood and Adolescence
- Ovarian, Fallopian Tube, and Peritoneal Cancer
- Pancreatic Cancer
- Parathyroid Cancer
- Penile Cancer
- Peutz-Jeghers Syndrome
- Pheochromocytoma and Paraganglioma
- Pituitary Gland Tumor
- Pleuropulmonary Blastoma - Childhood
- Retinoblastoma - Childhood
- Rhabdomyosarcoma - Childhood
- Salivary Gland Cancer
- Sarcoma - Kaposi
- Sarcomas, Soft Tissue
- Skin Cancer (Non-Melanoma)
- Small Bowel Cancer
- Stomach Cancer
- Testicular Cancer
- Thymoma and Thymic Carcinoma
- Thyroid Cancer
- Tuberous Sclerosis Complex
- Unknown Primary
- Uterine Cancer
- Vaginal Cancer
- Von Hippel-Lindau Syndrome
- Vulvar Cancer
- Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
- Werner Syndrome
- Wilms Tumor - Childhood
- Xeroderma Pigmentosum
- Veterans with Cancer
- Insurance and Cancer
- Prayers for Cancer Healing
- Prayers for Cancer Survival
- Pharmacology - Cancer Oncology drugs
- Natural Cures for Cancer
- Cancer Causing Foods
- Cancer Fighting Foods
- Kaposi Sarcoma
- Nausea and Vomiting in Cancer
- Adrenocortical Carcinoma
- Adolescents and Young Adults with Cancer
- Basal Cell Carcinoma of the Skin
- Burkitt Lymphoma
- Pancreatic Cancer
- Pain Management in Cancer
- CBD and Cancer Patients
- Cancer Treatment
- Stoma Bag
- Cancer Bra
- Cancer Wigs
- Lymphedema and Cancer
- Ductal Carcinoma In Situ (DCIS)
- Mouth Cancer
- Pregnancy and Breast Cancer
- Endometrial Cancer
- Heart Tumors, Childhood
- Merkel Cell Carcinoma
- Urethral Cancer
- Cancer in Young Adults
- Exercise and Cancer
- Insurance Denial and Cancer
- Bronchial Tumors
- Colostomy and Cancer
- Tube Feeding and Cancer
- Chronic Myeloproliferative Neoplasms
- Pulmonary Inflammatory Myofibroblastic Tumor
- Cutaneous T-Cell Lymphoma
- Fallopian Tube Cancer
- Breast Prostheses after Mastectomy
- Vascular Tumors
- Urethral cancer
- Music
Up next
Virtual Roadshow with Ayala Pharmaceuticals (AYLA) CEO Roni Mamluk
Originally broadcast LIVE May 6, 2021. Ayala Pharmaceuticals CEO Roni Mamluk makes a formal corporate presentation. Afterwards, she is joined by Noble Capital Markets Senior Research Analyst Robert LeBoyer for a Q & A session featuring questions asked by the live audience throughout the event.
Research, News, and Advanced Market Data on AYLA is available at no cost on Channelchek: https://www.channelchek.com/company/AYLA
Information on upcoming live virtual roadshows is available on Channelchek: https://www.channelchek.com/vrs
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trial for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com.
SORT BY-
Top Comments
-
Latest comments